NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NYSE American · Biotechnology · USD

OS Therapies Incorporated (OSTX) Stock Analysis

OS Therapies Incorporated (OSTX) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

OSTX

$1.88

+$0.06 (+3.30%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OSTX with… →

OSTX Key Statistics

As of Sep 4, 2026
Trading
Open
$1.84
Previous Close
$1.82
Day's Range
1.84–1.96
52-Week Range
1.15–2.35
Volume
982.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.68
Valuation
Market Cap
$87.37M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
5.81
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.09
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$28.75M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
46.47M
1-Year Return
−10.05%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
551.77K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

OSTX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+34.29%
2025−67.29%
2024 (partial year)+70.52%

As of September 4, 2026.

OSTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$28.75M—
2024$0.00−$8.88M—
2023$0.00−$7.79M—
2022$0.00−$6.25M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$28.71M−$28.75M—
2024$0.00—−$6.81M−$8.88M—
2023$0.00—−$4.34M−$7.79M—
2022$0.00—−$4.45M−$6.25M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OSTX Valuation vs Biotechnology Median

Median of 656 stocks
MetricOSTXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values OS Therapies Incorporated (OSTX) at $87.37M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 4 employees.

Over the past 52 weeks the price has ranged from $1.15 to $2.35. OSTX last closed at $1.88 on September 4, 2026. That is +$0.06 (+3.30%) against the previous close. The latest close sits 63.48% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $28.75M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.09.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 5.81.

The trailing one-year price return is −10.05%. The stored price history starts on August 1, 2024, and the total return since then is −25.10%. Beta against the wider market is reported at −0.68. Daily returns over the trailing 2 years annualize to a volatility of 104.51%.

Growth & Income

The record shows no dividend for OSTX.

The record holds one complete calendar year, 2025, which returned −67.29%. So far in 2026 the price is +34.29%.

Peer Comparison

OS Therapies Incorporated (OSTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
OS Therapies Incorporated OSTX $87.37M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. OS Therapies Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About OS Therapies Incorporated

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.

Visit website →